AU2001235006A1 - Prophylactic and therapeutic monoclonal antibodies - Google Patents
Prophylactic and therapeutic monoclonal antibodiesInfo
- Publication number
- AU2001235006A1 AU2001235006A1 AU2001235006A AU3500601A AU2001235006A1 AU 2001235006 A1 AU2001235006 A1 AU 2001235006A1 AU 2001235006 A AU2001235006 A AU 2001235006A AU 3500601 A AU3500601 A AU 3500601A AU 2001235006 A1 AU2001235006 A1 AU 2001235006A1
- Authority
- AU
- Australia
- Prior art keywords
- monoclonal antibodies
- prophylactic
- therapeutic monoclonal
- antibodies
- mixtures
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Abstract
In this application are described vaccinia monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of vaccinia virus infections in vitro and in vivo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18206600P | 2000-02-11 | 2000-02-11 | |
US60182066 | 2000-02-11 | ||
PCT/US2001/004520 WO2001058485A2 (en) | 2000-02-11 | 2001-02-09 | Prophylactic and therapeutic antibodies against vaccina virus antigens |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001235006A1 true AU2001235006A1 (en) | 2001-08-20 |
Family
ID=22666929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001235006A Abandoned AU2001235006A1 (en) | 2000-02-11 | 2001-02-09 | Prophylactic and therapeutic monoclonal antibodies |
Country Status (6)
Country | Link |
---|---|
US (2) | US6451309B2 (en) |
EP (1) | EP1309348B1 (en) |
AT (1) | ATE419872T1 (en) |
AU (1) | AU2001235006A1 (en) |
DE (1) | DE60137337D1 (en) |
WO (1) | WO2001058485A2 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000275666A (en) * | 1999-03-25 | 2000-10-06 | Hitachi Ltd | Liquid crystal display device |
AU2003215116A1 (en) * | 2002-02-11 | 2003-09-04 | Alexion Pharmaceuticals, Inc. | Human antibodies for therapy against vaccinia or smallpox |
US6982156B2 (en) * | 2002-03-27 | 2006-01-03 | Trustees Of The University Of Pennsylvania | Compositions and methods modulating variola and vaccinia virus |
GB0212666D0 (en) | 2002-05-31 | 2002-07-10 | Secr Defence | Immunogenic sequences |
US20060003316A1 (en) * | 2002-07-15 | 2006-01-05 | John Simard | Immunogenic compositions derived from poxviruses and methods of using same |
WO2004053454A2 (en) * | 2002-11-27 | 2004-06-24 | Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health | Methods for detecting invasion of a cell |
US20040185022A1 (en) * | 2003-02-19 | 2004-09-23 | Steven Rubin | Regimen for acne treatment |
AU2004262506A1 (en) * | 2003-02-28 | 2005-02-17 | National Institutes Of Health | Compositions, methods and kits relating to poxvirus subunit vaccines |
WO2005003325A2 (en) * | 2003-03-11 | 2005-01-13 | Dana Farber Cancer Institute | Inhibition of viral pathogenesis |
US20050009110A1 (en) * | 2003-07-08 | 2005-01-13 | Xiao-Jia Chang | Methods of producing antibodies for diagnostics and therapeutics |
AU2005255019B2 (en) * | 2004-06-12 | 2011-05-19 | Oregon Health And Science University | Compositions and methods for diagnosis and treatment of orthopoxviruses |
JP2008503217A (en) * | 2004-06-18 | 2008-02-07 | アンブレツクス・インコーポレイテツド | Novel antigen-binding polypeptides and their use |
US7393533B1 (en) * | 2004-11-08 | 2008-07-01 | La Jolla Institute For Allergy And Immunology | H3L envelope protein immunization methods and H3L envelope passive protection methods |
WO2007028985A2 (en) * | 2005-09-07 | 2007-03-15 | The Secretary Of State For Defence | Adjuvanted vaccine |
US7790182B2 (en) * | 2005-09-21 | 2010-09-07 | The United States Of America As Represented By The Secretary Of The Army | Protein vaccines against poxviruses |
US7850965B2 (en) * | 2005-12-05 | 2010-12-14 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
EP2040744B1 (en) | 2006-07-25 | 2016-03-09 | The Secretary of State for Defence | Live vaccine strains of francisella |
CA2661659C (en) * | 2006-08-23 | 2015-10-13 | Quercegen Pharma Llc | Smallpox monoclonal antibody |
EP2121720A4 (en) | 2007-02-12 | 2010-05-12 | Us Army | Puumala virus full-length m segment-based dna vaccines |
US8513005B2 (en) * | 2007-07-09 | 2013-08-20 | The United States Of America As Represented By The Secretary Of The Army | DNA immunogenic composition comprising a full-length modified poxvirus L1R gene fused to a tPA leader sequence |
WO2009117030A2 (en) * | 2007-12-19 | 2009-09-24 | Macrogenics, Inc. | Improved compositions for the prevention and treatment of smallpox |
GB0906234D0 (en) | 2009-04-14 | 2009-05-20 | Secr Defence | Vaccine |
WO2012105931A2 (en) | 2011-01-31 | 2012-08-09 | The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The United States Army | Sin nombre virus full-length m segment-based dna vaccine |
US9861681B2 (en) | 2013-04-18 | 2018-01-09 | The United States of America as represented by the Secretary of the Army, on behalf of the United States Army Medical Research Institute of Infectious Diseases | Therapeutic compositions for neutralizing type I interferons, and methods of use |
DE102015107577A1 (en) * | 2015-05-13 | 2016-11-17 | Osram Opto Semiconductors Gmbh | Optoelectronic semiconductor chip |
US10381278B2 (en) * | 2017-09-14 | 2019-08-13 | Powertech Technology Inc. | Testing method of packaging process and packaging structure |
-
2001
- 2001-02-09 US US09/781,124 patent/US6451309B2/en not_active Expired - Lifetime
- 2001-02-09 DE DE60137337T patent/DE60137337D1/en not_active Expired - Fee Related
- 2001-02-09 WO PCT/US2001/004520 patent/WO2001058485A2/en active Application Filing
- 2001-02-09 AU AU2001235006A patent/AU2001235006A1/en not_active Abandoned
- 2001-02-09 EP EP01907203A patent/EP1309348B1/en not_active Expired - Lifetime
- 2001-02-09 AT AT01907203T patent/ATE419872T1/en not_active IP Right Cessation
-
2002
- 2002-09-16 US US10/202,532 patent/US6620412B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US6451309B2 (en) | 2002-09-17 |
ATE419872T1 (en) | 2009-01-15 |
EP1309348B1 (en) | 2009-01-07 |
DE60137337D1 (en) | 2009-02-26 |
US6620412B2 (en) | 2003-09-16 |
US20030022226A1 (en) | 2003-01-30 |
US20020009447A1 (en) | 2002-01-24 |
WO2001058485A2 (en) | 2001-08-16 |
WO2001058485A3 (en) | 2002-01-10 |
EP1309348A2 (en) | 2003-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001235006A1 (en) | Prophylactic and therapeutic monoclonal antibodies | |
WO2001014424A3 (en) | Human ctla-4 antibodies and their uses | |
WO2003011115A3 (en) | Peptide-based multimeric targeted contrast agents | |
TR200002773T2 (en) | Smilagen and anzurogenin-D and their use for the treatment of Alzheimer's. | |
WO2004018649A3 (en) | Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein | |
WO2004028454A3 (en) | 1, 3, 5-triazines for treatment of viral diseases | |
WO2002074337A8 (en) | Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases | |
MY136095A (en) | Use of human anti-ctla-4 antibodies for treatment of cancer | |
WO2002078766A3 (en) | Combination therapy | |
MXPA02011656A (en) | Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods. | |
WO2004006858A3 (en) | Compounds, compositions, and methods employing same | |
PL328858A1 (en) | Immunogenous peptides | |
EP1381280A4 (en) | Viral vectors and their use in therapeutic methods | |
IL153680A0 (en) | Aplidine derivatives and methods for the preparation thereof | |
AUPP589598A0 (en) | Novel peptides | |
MXPA02012249A (en) | Peptides, compositions and methods for the treatment of burkholderia cepacia. | |
MXPA03003741A (en) | Methods and compositions for the treatment of diseases of the eye. | |
YU68602A (en) | Monoclonal antibodies to the human ldl receptor, their production and use | |
WO2003031585A3 (en) | Transmembrane serine protease 25 | |
WO2001040473A3 (en) | Pseudomonas aeruginosa antigens | |
WO2003004517A3 (en) | Peyers's patch and/or m-celle targeting ligands | |
WO2002066492A3 (en) | Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof | |
AU2002365104A1 (en) | Method for the diagnosis of breast cancer diseases, associated peptides and the uses thereof | |
EP1370697A4 (en) | Peroxiredoxin drugs for treatment of hiv-1 infection and methods of use thereof | |
WO2003039455A3 (en) | Methods of treating endometreosis |